Core Insights - Argenx SE will present data for VYVGART and pipeline candidates at the 2026 American Academy of Neurology Annual Meeting, highlighting advancements in treatments for severe autoimmune diseases [1][2] Group 1: VYVGART Developments - New Phase 3 results in ocular myasthenia gravis (oMG) will demonstrate VYVGART's potential as a targeted treatment option for patients [2][5] - Positive results from the Phase 3 ADAPT OCULUS study confirm VYVGART's therapeutic potential in adults with oMG, marking a significant advancement in treatment options [6] - Data from the ADAPT SERON study supports VYVGART's efficacy across broader patient populations, including generalized myasthenia gravis (gMG) patients without detectable anti-acetylcholine receptor antibodies [6][39] Group 2: Pipeline Candidates - Argenx will share results from the ARGX-119 Phase 1b trial evaluating adimanebart in patients with DOK7 congenital myasthenic syndromes, showing a favorable safety profile and functional improvements [4][39] - Empasiprubart, a novel monoclonal antibody, is being evaluated for multiple severe autoimmune indications, including chronic inflammatory demyelinating polyneuropathy (CIDP) [29] Group 3: CIDP Insights - Results from an ADHERE post hoc analysis will highlight VYVGART Hytrulo's impact in treatment-naïve CIDP patients, supporting its earlier use in treatment paradigms [3][39] - Real-world insights will illustrate physician approaches to transitioning patients from intravenous immunoglobulin to VYVGART Hytrulo, aiming to enhance patient outcomes [39] Group 4: Presentation Details - The presentations at the AAN Annual Meeting will include various studies on myasthenia gravis and CIDP, showcasing the breadth of research and data supporting VYVGART and its pipeline candidates [4][6][7]

Core Insights - Argenx SE will present data for VYVGART and pipeline candidates at the 2026 American Academy of Neurology Annual Meeting, highlighting advancements in treatments for severe autoimmune diseases [1][2][36] Group 1: VYVGART Developments - New Phase 3 results in ocular myasthenia gravis (oMG) will demonstrate VYVGART's potential as a targeted treatment option for patients [2][6] - Positive results from the Phase 3 ADAPT OCULUS study confirm VYVGART's therapeutic potential in adults with oMG, marking a significant advancement in treatment options [5][6] - Data from the ADAPT SERON study supports VYVGART's efficacy across broader patient populations, including generalized myasthenia gravis (gMG) patients without detectable anti-acetylcholine receptor antibodies [6][38] Group 2: Pipeline Candidates - Argenx will share results from the ARGX-119 Phase 1b trial evaluating adimanebart in patients with DOK7 congenital myasthenic syndromes, showing a favorable safety profile and functional improvements [4][38] - Empasiprubart is being evaluated for multiple severe autoimmune indications, including chronic inflammatory demyelinating polyneuropathy (CIDP) and delayed graft function following kidney transplant [28][36] Group 3: CIDP Insights - Results from an ADHERE post hoc analysis will highlight VYVGART Hytrulo's impact in treatment-naïve CIDP patients, supporting its earlier use in treatment paradigms [3][38] - Real-world insights will illustrate physician approaches to transitioning patients from intravenous immunoglobulin (IVIg) to VYVGART Hytrulo, aiming to enhance patient outcomes [3][38]

Summary of Argenx Conference Call Company Overview - **Company**: Argenx - **Event**: 46th Annual TD Cowen Healthcare Conference - **New CEO**: Karen Massey Key Points and Arguments Vision and Strategic Focus - Argenx 2.0 is a growth story focused on innovation, aiming to reach 50,000 patients by the end of the decade with 10 labeled indications and 5 molecules in late-stage development [4][5] - Short-term growth is expected from upcoming readouts in myositis and VYVGART for MMN, with plans for Sjögren's and CIDP in the future [5][6] Product Pipeline and Development - The FcRn strategy includes two next-generation molecules and an oral formulation, expanding the pipeline beyond FcRn [5][6] - Early-stage programs are being developed, including a recent deal with Tensegrity [6] VYVGART Performance - VYVGART has shown strong year-on-year growth, with a PDUFA date in May for seronegative MG patients and positive ocular MG data [23][24] - The company has reached $1 billion in sales, with CIDP accounting for approximately 35% of sales [26][27] - VYVGART is positioned as the number one prescribed biologic in MG, with a focus on removing friction for prescribers regarding antibody status [28][29] Market Dynamics and Competition - The company is aware of competition but believes VYVGART's safety profile and efficacy position it well against alternatives [59] - The market for MG treatments is evolving, with FcRns being used as first-line therapies, while C5 therapies are reserved for refractory patients [32][35] Myositis and Clinical Trials - The myositis trial is designed to assess efficacy across multiple subtypes, allowing flexibility in approval based on data [67][68] - The prevalence of DM and MMN is highlighted, with a focus on the unmet need in IMN [73][74] Sjögren's and Future Studies - The company is optimistic about the Sjögren's program, with plans for additional evidence generation following positive readouts [90][91] EMPA and CIDP Strategy - EMPA is positioned to transform outcomes for CIDP patients, with a focus on biomarker data and understanding patient heterogeneity [115][116] - The company is also exploring combination studies in MG, indicating a broad strategy for future indications [118][120] IgA Sweeper Development - The IgA sweeper is being developed for IgA nephropathy (IgAN) with plans for further indications like IgA vasculitis [124][129] Additional Important Insights - The company emphasizes the importance of treating ocular MG, as it significantly impacts patients' quality of life [51][52] - The competitive landscape is acknowledged, with a focus on differentiating VYVGART through its unique dosing options and safety profile [59][60] This summary encapsulates the key discussions and strategic directions presented during the conference call, highlighting Argenx's commitment to innovation and growth in the biotech sector.

Financial Data and Key Metrics Changes - Product net sales for Q4 2025 were $1.3 billion, and for the full year, they reached $4.2 billion, representing a year-over-year growth of 90% [16][18] - Operating profit for Q4 was $367 million, and for the full year, it was $1.1 billion, marking the first year of annual operating profitability [18] - Cash balance at the end of Q4 was $4.4 billion, an increase of over $1 billion from the previous year [18] Business Line Data and Key Metrics Changes - VYVGART is leading the growth in both Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), with significant patient adoption and label expansion opportunities [9][22] - The company reached 19,000 patients globally, driven by the successful launch of the prefilled syringe for self-injection [7][20] - In CIDP, the company is beginning to see expansion beyond the initial 12,000 addressable patients, with a focus on continued evidence generation and patient activation [11][39] Market Data and Key Metrics Changes - In Q4 2025, product revenue breakdown included $1.1 billion in the U.S., $63 million in Japan, $110 million in the rest of the world, and $26 million in products supplied to Zai Lab in China [16] - The U.S. product net sales grew by 68% from the fourth quarter of the prior year, reflecting solid patient demand and prescriber confidence [16] Company Strategy and Development Direction - The company aims to impact more patients globally with VYVGART through broader patient adoption and label expansion, focusing on next-generation molecules and combination approaches [8][9] - The strategic priorities for 2026 include advancing the immunology pipeline and delivering at least one new pipeline candidate per year [8][12] - The company is committed to expanding its reach into autoimmune myositis and Sjögren's disease, addressing significant unmet needs [11][12] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the growth trajectory of VYVGART, particularly with the upcoming PDUFA date for seronegative MG and the positive results for ocular MG [31][32] - The leadership transition is seen as timely, with the company well-positioned for its next phase of growth [26][78] - Management highlighted the importance of maintaining a strong balance sheet to support ongoing investments in the commercial business and pipeline [18][96] Other Important Information - The company is advancing two next-generation assets, ARGX-213 and ARGX-124, to enhance patient experience and expand indications [12][70] - The prefilled syringe has proven to be a key driver in increasing overall VYVGART demand, with over 4,700 prescribers at the end of Q4 [20][21] Q&A Session Summary Question: On the addition of seronegative and ocular MG to the revenue stream for VYVGART - Management confirmed that VYVGART is the first and only therapy with positive data for ocular MG, positioning the company well for sustained growth in MG [31] - The addressable market for ocular MG is estimated at 7,000 patients, with ongoing market research to refine these estimates [32] Question: On the CIDP opportunity and coverage expansion - Management noted that CIDP growth is primarily from patients switching from IVIG, with recent coverage expansion to over 90% of covered lives expected to enhance adoption rates [39] Question: On the impact of ocular MG approval on less advanced MG patients - Management indicated that the ocular MG data will support the strategy to expand biologic use to earlier lines of treatment in MG [42] Question: On Q1 dynamics and growth expectations - Management acknowledged seasonal dynamics affecting Q1 performance but expressed confidence in the underlying growth drivers for the full year [49][50] Question: On VYVGART growth dynamics and competitive landscape - Management emphasized continued growth across all indications and formulations, welcoming competition as a sign of market expansion [89][90]

Financial Data and Key Metrics Changes - Product net sales for Q4 2025 were $1.3 billion, and for the full year, they reached $4.2 billion, reflecting a year-over-year growth of 90% [16] - Operating profit for Q4 was $367 million, and for the full year, it was $1.1 billion, marking the first year of annual operating profitability [18] - Cash balance at the end of Q4 was $4.4 billion, representing an increase of over $1 billion for the year [18] Business Line Data and Key Metrics Changes - VYVGART is leading the growth in both Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), with significant patient adoption and label expansion opportunities [9][10] - The company reached approximately 19,000 patients globally by the end of 2025, driven by the successful launch of the prefilled syringe for self-injection [20] - In CIDP, the company is beginning to see expansion beyond the initial 12,000 addressable patients, with a focus on continued evidence generation and patient activation [39] Market Data and Key Metrics Changes - In Q4 2025, product revenue breakdown included $1.1 billion in the U.S., $63 million in Japan, $110 million in the rest of the world, and $26 million in products supplied to Zai Lab in China [16] - The U.S. product net sales grew by 68% from the fourth quarter of the prior year, reflecting solid patient demand and prescriber confidence [16] Company Strategy and Development Direction - The company aims to impact more patients globally with VYVGART through broader patient adoption and label expansion, with a goal of at least one new pipeline candidate per year [8][9] - The strategic priorities for 2026 include advancing the immunology pipeline and expanding into new patient populations, including autoimmune myositis and Sjögren's disease [11][12] - The company is committed to establishing FcRn leadership for decades to come, with investments in next-generation assets and innovative delivery modalities [12][13] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the growth trajectory of VYVGART, particularly with the upcoming PDUFA date for seronegative MG and the positive results for ocular MG [31][32] - The company anticipates continued revenue growth exceeding operating expense growth, leading to increased operating margins over time [95] - Management highlighted the importance of maintaining a strong balance sheet to support ongoing investments in the commercial business and pipeline [18][96] Other Important Information - The company is advancing two next-generation assets, ARGX-213 and ARGX-124, to enhance patient experience and expand indications [12][70] - The prefilled syringe has proven to be a key driver in increasing overall VYVGART demand, with over 4,700 prescribers by the end of Q4 2025 [20][21] Q&A Session Summary Question: What is the expected average price for seronegative and ocular MG indications? - Management indicated that they expect a similar price to MG, approximately $225,000 net price to argenx, pending discussions with payers [34] Question: Can you elaborate on the CIDP opportunity and its expansion? - Management noted that they are beginning to see use beyond the initial 12,000 patients, with a focus on continued growth and evidence generation [39] Question: Will approval in ocular MG drive more utilization in less advanced MG patients? - Management believes that the ocular MG data will support the strategy of expanding biologic use to earlier lines of MG treatment [42] Question: What are the dynamics to consider for Q1? - Management acknowledged seasonal dynamics affecting Q1, including reverifications and winter storms, but expects continued growth based on healthy underlying dynamics [49][50] Question: How should we think about the sustainability of VYVGART's growth profile? - Management emphasized that revenue growth should exceed operating expense growth, leading to a sustainable and profitable business model [95][96]

Certain statements contained in this presentation, other than present and historical facts and conditions independently verifiable at the date hereof, may constitute forward-looking statements. These forward-looking statements can be identified by the use of forward-looking terminology, including the terms "advance," "broaden," "build," "deliver," and "expand," and include statements argenx makes regarding its new era of innovation in immunology; its advancement of its Vision 2030, including (1) 5 new molec ...

Core Insights - Argenx SE – ADR (NASDAQ:ARGX) is recognized as a promising healthcare stock for 2026, particularly following the FDA's acceptance of a priority review for its drug Vyvgart [1][2] Group 1: FDA Review and Drug Indication - The FDA has granted priority review status for a supplemental biologics license application aimed at expanding Vyvgart's use for treating adults with acetylcholine receptor antibody-seronegative generalized myasthenia gravis (gMG) [2] - If the application is successful, it will broaden the patient population eligible for Vyvgart, potentially increasing its market reach [2] Group 2: Sales Momentum and Market Sentiment - William Blair has reiterated an Outperform rating on Argenx, citing strong sales momentum in the Vyvgart franchise, with sales exceeding expectations [3] - The positive sales trend is anticipated to continue through 2026 across indications in myasthenia gravis (MG) and chronic inflammatory demyelinating polyneuropathy (CIDP) [3] Group 3: Company Overview - Argenx SE is a Netherlands-based global biotechnology company focused on developing, manufacturing, and commercializing antibody-based therapies for severe autoimmune diseases and cancers [4]

Group 1 - Argenx SE (NASDAQ:ARGX) is recognized as one of the top high-growth European stocks, with an Outperform rating maintained by William Blair due to strong sales growth in its Vyvgart brand [1] - Vyvgart sales are exceeding expectations and are expected to maintain solid momentum through 2026 for applications in myasthenia gravis (MG) and chronic inflammatory demyelinating polyneuropathy (CIDP) [1] - The FDA has agreed to prioritize a supplemental biologics licensing application for Vyvgart, which aims to expand its use in treating adults with acetylcholine receptor antibody-seronegative generalized myasthenia gravis (gMG) [3] Group 2 - Argenx is developing treatments for severe autoimmune diseases and operates in four segments: the United States, Japan, EMEA, and China [4] - The company has other clinical products in development, such as empasiprubart for multifocal motor neuropathy (MMN), with pivotal data expected in the fourth quarter of 2026 [2]

Core Thesis - Argenx SE is experiencing strong momentum driven by the success of its therapy VYVGART, which generated over $4.1 billion in 2025, nearly doubling year-on-year [2][4]. Company Overview - Argenx SE is a commercial-stage biopharma company focused on developing therapies for autoimmune diseases across various countries including the United States, Japan, China, and the Netherlands [2]. Financial Performance - As of January 26th, Argenx's share price was $833.16, with trailing and forward P/E ratios of 35.64 and 27.93 respectively [1]. Product Development and Strategy - VYVGART has evolved into a durable franchise with multiple growth levers, focusing on expanding the addressable patient population rather than just proving demand [4]. - Key priorities for 2026 include broadening VYVGART's global footprint and extending its reach into additional indications such as seronegative and ocular MG, immune thrombocytopenia, myositis, and Sjögren's disease [4]. - The company is also advancing its leadership in FcRn biology through next-generation molecules and new delivery formats, including a planned autoinjector in 2027 [5]. Pipeline and Future Outlook - Argenx is building a robust pipeline with approximately ten registrational studies ongoing and ten molecules in clinical development by year-end, including first-in-class programs [5]. - The company has transitioned from a single-asset biotech to a platform-driven organization, with VYVGART providing scale, cash flow, and credibility, while the growing pipeline reduces concentration risk [6]. - With continued execution, Argenx is positioned as a long-duration immunology compounder with multiple opportunities for sustained value creation [6].

Core Insights - argenx reported preliminary full-year 2025 global product net sales of $4.15 billion, reflecting a year-over-year growth of 90%, with fourth quarter sales contributing approximately $1.29 billion [1][15] - The company aims to impact over 50,000 patients globally with its medicines and has set strategic priorities for 2026, including expanding the use of VYVGART and advancing its pipeline towards Vision 2030 [4][3] Financial Performance - Preliminary global product net sales for the fourth quarter of 2025 were approximately $1.29 billion, while full-year sales reached $4.15 billion [15][16] - The reported growth of 90% year-over-year indicates strong market performance and demand for argenx's products [1] Product Pipeline and Development - VYVGART continues to lead the growth in the market for myasthenia gravis (MG) and chronic inflammatory demyelinating polyneuropathy (CIDP), with around 19,000 patients currently on treatment [3][4] - The company has four registrational readouts expected in 2026, including the first for empasiprubart, which is part of the next wave of commercial launches planned for 2027 [1][3] - By the end of 2026, argenx anticipates having a total of 10 clinical-stage molecules, with three new molecules entering Phase 1 trials [1][8] Strategic Priorities for 2026 - The company aims to broaden the adoption of VYVGART and unlock new opportunities through potential label expansions, including a launch for AChR-Ab seronegative gMG expected by the end of 2026 [4][10] - argenx is focused on shaping the long-term future of FcRn medicines by advancing new pipeline candidates and innovative delivery modalities [5][7] - The strategic priorities include delivering the next wave of immunology innovation, with empasiprubart and a diversified pipeline of first-in-class molecules [5][8] Leadership Changes - Upcoming leadership transitions include Karen Massey becoming the new Chief Executive Officer, while Tim Van Hauwermeiren will transition to a non-Executive Director role [13][14] - These changes are subject to shareholder approval at the Annual General Meeting scheduled for May 6, 2026 [13]